Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study
Ming-Han Tsai,Chyi-Liang Chen,Hsin-Ju Chang,Tzu-Chun Chuang,Cheng-Hsun Chiu
DOI: https://doi.org/10.1016/j.jgar.2024.03.014
IF: 4.349
2024-03-29
Journal of Global Antimicrobial Resistance
Abstract:Objectives Eravacycline, a new tetracycline derivative, exhibits broad-spectrum antimicrobial susceptibility. This study aimed to comprehensively investigate in-vitro activities of eravacycline, tigecycline, and ertapenem against various Gram-positive, Gram-negative, and anaerobic bacteria. Methods Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. The following bacterial species were collected: vancomycin-sensitive (VS) Enterococci species, vancomycin-resistant Enterococci species (VRE), Staphylococcus aureus, Streptococcus anginosus, Bacteroides species, Clostridioides difficile, Clostridium innocuum, Clostridium perfringens, Parabacteroides distasonis , and Stenotrophomonas maltophilia . Results We found that eravacycline exhibited superior in vitro activity compared to tigecycline and ertapenem. Notably, it exhibited the lowest MIC 90 for several bacterial species, including VS E. faecalis (0.12 μ g/mL), VS E. faecium (0.12 μ g/mL), and others. Besides, VRE was susceptible to eravacycline (MIC 90 :0.12 μ g/mL) and tigecycline (MIC 90 :0.12 μ g/mL), but was all resistant to ertapenem (MIC 90 >64 μ g/mL). S. aureus was also susceptible to eravacycline (MIC 90 :0.5 μ g/mL) as well as tigecycline (MIC 90 :1.0 μ g/mL). Furthermore, S. anginosus showed higher susceptibility to eravacycline (MIC 90 :2.0 μ g/mL) and tigecycline (MIC 90 :4.0 μ g/mL), but lower to ertapenem (MIC 90 :32.0 μ g/mL). Eravacycline and tigecycline also demonstrated good susceptibility to anaerobes, including Bacteroides species (susceptibility rate: 100%), P. distasonis (100%), C. difficile (94.1‒100%), C. innocuum (94.1‒96.1%), and C. perfringens (88.9‒96.3%). For S. maltophilia , both tigecycline and eravacycline showed an MIC 90 of 2 μ g/mL. A moderate-to-strong correlation (rho=0.608-0.804, P < 0.001) was noted between the MIC values of eravacycline and tigecycline against various bacterial species. Conclusions Our study highlights the potential of eravacycline as an effective treatment option for multidrug-resistant bacterial infections.
pharmacology & pharmacy,infectious diseases